Cover Story
Conversation with The Cancer Letter
James Allison has reshaped cancer drug development, making checkpoint inhibitors a staple of therapy in many key indications—and dramatically improving survival outcomes in previously recalcitrant diseases.
In Brief
Funding Opportunities
Clinical Roundup
